ES2607616T3 - Modelo animal no humano para la colitis ulcerosa y sus principales complicaciones - Google Patents

Modelo animal no humano para la colitis ulcerosa y sus principales complicaciones Download PDF

Info

Publication number
ES2607616T3
ES2607616T3 ES12738593.8T ES12738593T ES2607616T3 ES 2607616 T3 ES2607616 T3 ES 2607616T3 ES 12738593 T ES12738593 T ES 12738593T ES 2607616 T3 ES2607616 T3 ES 2607616T3
Authority
ES
Spain
Prior art keywords
ulcerative colitis
animal model
human animal
nox1
main complications
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12738593.8T
Other languages
English (en)
Inventor
Eric Ogier-Denis
Xavier Treton
Fanny DANIEL
Cécile GUICHARD
Eric PEDRUZZI
Yoram BOUHNIK
Yann HARNOY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Application granted granted Critical
Publication of ES2607616T3 publication Critical patent/ES2607616T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/02—Breeding vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0325—Animal model for autoimmune diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8527—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic for producing animal models, e.g. for tests or diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Environmental Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)

Abstract

Un modelo animal transgénico no humano para la colitis ulcerosa y sus principales complicaciones, tales como la colangitis esclerosante primaria y el cáncer colorrectal, que comprende una alteración dirigida en los genes de la interleucina 10 (IL10) y de la oxidasa de NADPH 1 (NOX1), de 5 forma que la IL10 y la NOX1 no son expresadas en dicho animal, y en el que se lleva a cabo una apendicectomía o una extirpación del suelo cecal en el animal.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
5
10
15
20
25
30
35
40
45
50
55
60
spontaneous inflammation resembling ulcerative colitis. PLoS Med 5, e54 (2008).
8.
Shkoda, A., et al. Interleukin-10 blocked endoplasmic reticulum stress in intestinal epithelial cells: impact on chronic inflammation. Gastroenterology 132, 190-207 (2007).
9.
Turner, M. J., et al. HLA-B27 misfolding in transgenic rats is associated with activation of the unfolded protein response. J Immunol 175, 2438-2448 (2005).
10.
Coant, N., et al. NADPH oxidase 1 modulates WNT and NOTCH1 signaling to control the fate of proliferative progenitor cells in the colon. Mol Cell Biol 30, 2636-2650 (2010).
11.
Tytgat, K. M., van der Wal, J. W., Einerhand, A. W., Buller, H. A. y Dekker, J. Quantitative analysis of MUC2 synthesis in ulcerative colitis. Biochem Bio- phys Res Commun 224, 397-405 (1996).
12.
Gibson, P., Rosella, O., Nov, R. y Young, G. Colonic epithelium is diffusely abnormal in ulcerative colitis and colorectal cancer. Gut 36, 857-863 (1995).
13.
Ron, D. y Walter, P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol 8, 519-529 (2007).
14.
Zhang, K. y Kaufman, R. J. From endoplasmic-reticulum stress to the inflammatory response. Nature 454, 455-462 (2008).
15.
Van der Sluis, M., et al. Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology 131, 117-129 (2006).
16.
Velcich, A., et al. Colorectal cancer in mice genetically deficient in the mucin Muc2. Science 295, 1726-1729 (2002).
17.
Gregorieff, A., et al. The ets-domain transcription factor Spdef promotes maturation of goblet and paneth cells in the intestinal epithelium. Gastroenterology 137, 1333-1345 e1331-1333 (2009).
18.
Itoh, H., Beck, P. L., Inoue, N., Xavier, R. y Podolsky, D. K. A paradoxical reduction in susceptibility to colonic injury upon targeted transgenic ablation of goblet cells. J Clin Invest 104, 1539-1547 (1999).
19.
Shroyer, N. F., Wallis, D., Venken, K. J., Bellen, H. J. y Zoghbi, H. Y. Gfi1 functions downstream of Math1 to control intestinal secretory cell subtype allocation and differentiation. Genes Dev 19, 2412-2417 (2005).
20.
Yang, Q., Bermingham, N.A., Finegold, M. J. y Zoghbi, H. Y. Requirement of Math1 for secretory cell lineage commitment in the mouse intestine. Science 294, 2155-2158 (2001).
21.
Kuhn, R., Lohler, J., Rennick, D., Rajewsky, K. y Muller, W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75, 263-274 (1993).
22.
Jarry, A., et al. Mucosal IL-10 and TGF-beta play crucial roles in preventing LPS-driven, IFN-gamma- mediated epithelial damage in human colon explants. J Clin Invest 118, 1132-1142 (2008).
23.
Kamizato, M., et al. Interleukin 10 inhibits interferon gamma- and tumor necrosis factor alpha-stimulated activation of NADPH oxidase 1 in human colonic epithelial cells and the mouse colon. J Gastroenterol 44, 11721184 (2009).
24.
Valente, A. J., et al. Regulation of NOX1 expression by GATA, HNF-1alpha, and Cdx transcription factors. Free Radic Biol Med 44, 430-443 (2008).
25.
Szanto, I., et al. Expression of NOX1, a superoxide-generating NADPH oxidase, in colon cancer and inflammatory bowel disease. J Pathol 207, 164-176 (2005).
26.
Muise, A. M., et al. Single nucleotide polymorphisms that increase expression of the guanosine triphosphatase RAC1 are associated with ulcerative colitis. Gastroenterology 141,633-641 (2011).
27.
Cheng, G., Diebold, B. A., Hughes, Y. y Lambeth, J. D. Nox1-dependent reactive oxygen generation is regulated by Rac1. JBiol Chem 281, 17718-17726 (2006).
28.
Franke, A., et al. Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat Genet 40, 1319-1323 (2008).
29.
Kanneganti, M., Mino-Kenudson, M. y Mizoguchi, E. Animal models of colitis-associated carcinogenesis. J Biomed Biotechnol 2011, 342637 (2011).
30.
Fasseu, M., et al. Identification of restricted subsets of mature microRNA abnormally expressed in inactive colonic mucosa of patients with inflammatory bowel disease. PLoS One 5 (2010).
31.
Pekow, J. R. y Kwon, J. H. MicroRNAs in inflammatory bowel disease. Inflamm Bowel Dis 18, 187-193 (2011).
32.
Yu, Q. T., et al. Expression and functional characterization of FOXP3+ CD4+ regulatory T cells in ulcerative colitis. Inflamm Bowel Dis 13, 191-199 (2007).
33.
Scheuner, D., et al. Translational control is required for the unfolded protein response and in vivo glucose homeostasis. Mol Cell 7, 1165-1176 (2001).
34.
Jousse, C., et al. Inhibition of a constitutive translation initiation factor 2alpha phosphatase, CReP, promotes survival of stressed cells. J Cell Biol 163, 767-775 (2003).
35.
Boyce, M., et al. A selective inhibitor of eIF2alpha dephosphorylation protects cells from ER stress. Science 307, 935-939 (2005).
36.
Ruimy, R., et al. Phylogenetic analysis and assessment of the genera Vibrio, Photobacterium, Aeromonas, and Plesiomonas deduced from small- subunit rRNA sequences. Int J Syst Bacteriol 44, 416-426 (1994).
7

Claims (1)

  1. imagen1
ES12738593.8T 2011-04-13 2012-04-13 Modelo animal no humano para la colitis ulcerosa y sus principales complicaciones Active ES2607616T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11162272 2011-04-13
EP11162272 2011-04-13
PCT/IB2012/000882 WO2012140516A2 (en) 2011-04-13 2012-04-13 Non human animal model for ulcerative colitis and its main complications

Publications (1)

Publication Number Publication Date
ES2607616T3 true ES2607616T3 (es) 2017-04-03

Family

ID=44351492

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12738593.8T Active ES2607616T3 (es) 2011-04-13 2012-04-13 Modelo animal no humano para la colitis ulcerosa y sus principales complicaciones

Country Status (6)

Country Link
US (3) US20140031389A1 (es)
EP (2) EP2696859A1 (es)
JP (1) JP2014512008A (es)
CA (2) CA2832680A1 (es)
ES (1) ES2607616T3 (es)
WO (2) WO2012140208A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160124544A (ko) * 2015-04-20 2016-10-28 삼성전자주식회사 담즙울체성 간질환 동물 모델 및 이의 제조 방법
CN107912366B (zh) * 2017-12-06 2020-12-11 江苏珂玛麒生物科技有限公司 一种非酒精性慢性脂肪性肝炎非人灵长类动物模型及其构建方法和用途
JP7360106B2 (ja) 2017-12-28 2023-10-12 小胞体ストレス研究所株式会社 ベンゾチアゾイミダゾリル化合物を含有する小胞体ストレス調節剤
CN112913778B (zh) * 2021-01-29 2022-11-01 石河子大学 一种绵羊慢性炎症模型的构建方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763198A (en) 1994-07-22 1998-06-09 Sugen, Inc. Screening assays for compounds
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
US6566131B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of Smad6 expression
US6410323B1 (en) 1999-08-31 2002-06-25 Isis Pharmaceuticals, Inc. Antisense modulation of human Rho family gene expression
US6107091A (en) 1998-12-03 2000-08-22 Isis Pharmaceuticals Inc. Antisense inhibition of G-alpha-16 expression
US5981732A (en) 1998-12-04 1999-11-09 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-13 expression
US6046321A (en) 1999-04-09 2000-04-04 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-i1 expression
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
EP1272630A2 (en) 2000-03-16 2003-01-08 Genetica, Inc. Methods and compositions for rna interference
US6365354B1 (en) 2000-07-31 2002-04-02 Isis Pharmaceuticals, Inc. Antisense modulation of lysophospholipase I expression
US6566135B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of caspase 6 expression
WO2007084868A2 (en) * 2006-01-17 2007-07-26 Kalypsys, Inc. Treatment of disorders by activation of the unfolded protein response
AU2007220039A1 (en) * 2006-02-27 2007-09-07 The Board Of Trustees Of The Leland Stanford Junior University Inhibitors of the unfolded protein response and methods for their use
JP2008118870A (ja) * 2006-11-09 2008-05-29 Dainippon Sumitomo Pharma Co Ltd 自己免疫疾患治療剤のスクリーニング方法
WO2009137795A2 (en) * 2008-05-08 2009-11-12 University Of Massachusetts Methods for treating endoplasmic reticulum (er) stress disorders
US8268550B2 (en) * 2009-06-26 2012-09-18 Massachusetts Institute Of Technology Compositions and methods for identification of PARP function, inhibitors, and activators
ES2638370T3 (es) * 2009-11-23 2017-10-20 Inserm - Institut National De La Santé Et De La Recherche Médicale Inhibidores del complejo PP1/GADD34 para el tratamiento de una afección que requiera una actividad inmunosupresora

Also Published As

Publication number Publication date
CA2834960A1 (en) 2012-10-18
EP2696859A1 (en) 2014-02-19
CA2832680A1 (en) 2012-10-18
EP2696860B1 (en) 2016-10-19
WO2012140208A1 (en) 2012-10-18
WO2012140516A2 (en) 2012-10-18
US9217156B2 (en) 2015-12-22
US20140373186A1 (en) 2014-12-18
US20140031389A1 (en) 2014-01-30
EP2696860A2 (en) 2014-02-19
JP2014512008A (ja) 2014-05-19
WO2012140516A3 (en) 2012-11-29
US20160066551A1 (en) 2016-03-10

Similar Documents

Publication Publication Date Title
ES2607616T3 (es) Modelo animal no humano para la colitis ulcerosa y sus principales complicaciones
Yu et al. Effects of fish oil with a high content of n-3 polyunsaturated fatty acids on mouse gut microbiota
JP2015129189A5 (es)
AR090455A1 (es) Metodos para preparar analogos de nucleotidos sustituidos
ES2384701T1 (es) Utilización de DHA, EPA o EPA derivado de DHA destinado al tratamiento de una patología asociada al daño celular oxidativo
JP2013507940A5 (es)
JP2012532772A5 (es)
Hamilton et al. A murine model for cerebral toxocariasis: characterization of host susceptibility and behaviour
CL2011001692A1 (es) Composicion farmaceutica que entrega acido butirico y glutamina directamente en el colon, para inducir la liberacion de una hormona intestinal desde celulas l del colon; su uso en diabetes tipo i o tipo ii y obesidad, entre otros.
JP2015511821A5 (es)
JP2014527532A5 (es)
WO2009090639A3 (en) Sirna compounds and methods of use thereof
JP2015143248A5 (es)
JP2016520310A5 (es)
Jiang et al. Genetic variation in PICALM and Alzheimer's disease risk in Han Chinese
Wang et al. Integrated analysis neurimmiRs of tilapia (Oreochromis niloticus) involved in immune response to Streptococcus agalactiae, a pathogen causing meningoencephalitis in teleosts
Yan et al. Protective effect of baicalin on the small intestine in rats with food allergy
Drago et al. The efficacy of macrolides and acyclovir in pityriasis rosea
ES2528673B1 (es) Péptido con actividad inhibidora de quorum sensing, polinucleótido que codifica dicho péptido y sus aplicaciones
JP2012532856A5 (es)
JP2011157392A5 (es)
RU2449380C2 (ru) Способ определения степени устойчивости мелких лабораторных животных к циркуляторной гипоксии
Ulate-Campos et al. Síndrome de Down y epilepsia
Shimizu et al. Enhanced Th17 responses with intestinal dysbiosis in human allergic, inflammatory, and autoimmune diseases
Wu et al. Runx3 might participate in regulating dendriti cell function in patients with irritable bowel syndrome